ELIGIBLE MEDICATIONS
ViiVConnect offers savings and assistance programs for eligible medications*
See below for an overview of eligible medications
APRETUDE
(cabotegravir)
Extended-release injectable suspensions: cabotegravir 200 mg/mL
Eligible patients may also receive assistance with out-of-pocket costs associated with administration. For additional information, please read the full Eligibility Requirements and Restrictions.
Extended-release injectable suspensions: cabotegravir 200 mg/mL
Eligible patients may also receive assistance with out-of-pocket costs associated with administration. For additional information, please read the full Eligibility Requirements and Restrictions.
Extended-release injectable suspensions: cabotegravir 200 mg/mL
For more information, visit viivpap.org.
CABENUVA
(cabotegravir; rilpivirine)
Extended-release injectable suspensions: cabotegravir 200 mg/mL; rilpivirine 300 mg/mL
Eligible patients may also receive assistance with out-of-pocket costs associated with administration. For additional information, please read the full Eligibility Requirements and Restrictions.
Extended-release injectable suspensions: cabotegravir 200 mg/mL; rilpivirine 300 mg/mL
Eligible patients may also receive assistance with out-of-pocket costs associated with administration. For additional information, please read the full Eligibility Requirements and Restrictions.
Extended-release injectable suspensions: cabotegravir 200 mg/mL; rilpivirine 300 mg/mL
For more information, visit viivpap.org.
DOVATO
(dolutegravir and lamivudine)
Tablets: 50 mg dolutegravir and 300 mg lamivudine
For additional information, please read the full Eligibility Requirements and Restrictions.
Tablets: 50 mg dolutegravir and 300 mg lamivudine
For additional information, please read the full Eligibility Requirements and Restrictions.
Tablets: 50 mg dolutegravir and 300 mg lamivudine
For more information, visit viivpap.org.
EPIVIR
(lamivudine)
JULUCA
(dolutegravir and rilpivirine)
Tablets: 50 mg dolutegravir and 25 mg rilpivirine
For additional information, please read the full Eligibility Requirements and Restrictions.
Tablets: 50 mg dolutegravir and 25 mg rilpivirine
For additional information, please read the full Eligibility Requirements and Restrictions.
Tablets: 50 mg dolutegravir and 25 mg rilpivirine
For more information, visit viivpap.org.
RETROVIR
(zidovudine)
Capsules: 100 mg
Oral Solution: 10 mg/mL
Injection, for Intravenous use: 10 mg/mL (20 mL vial)
For more information, visit viivpap.org.
RUKOBIA
(fostemsavir)
Extended-Release Tablets: 600 mg
For additional information, please read the full Eligibility Requirements and Restrictions.
Extended-Release Tablets: 600 mg
For additional information, please read the full Eligibility Requirements and Restrictions.
Extended-Release Tablets: 600 mg
For more information, visit viivpap.org.
SELZENTRY
(maraviroc)
TIVICAY
(dolutegravir)
Tablets: 50 mg
For additional information, please read the full Eligibility Requirements and Restrictions.
Tablets: 50 mg
For additional information, please read the full Eligibility Requirements and Restrictions.
Tablets: 50 mg
For more information, visit viivpap.org.
TIVICAY PD
(dolutegravir)
Tablets for Oral Suspension: 5 mg
For additional information, please read the full Eligibility Requirements and Restrictions.
Tablets for Oral Suspension: 5 mg
For additional information, please read the full Eligibility Requirements and Restrictions.
Tablets for Oral Suspension: 5 mg
For more information, visit viivpap.org.
TRIUMEQ
(abacavir, dolutegravir, and lamivudine)
Tablets: 600 mg abacavir, 50 mg dolutegravir, and 300 mg lamivudine
For additional information, please read the full Eligibility Requirements and Restrictions.
Tablets: 600 mg abacavir, 50 mg dolutegravir, and 300 mg lamivudine
For additional information, please read the full Eligibility Requirements and Restrictions.
Tablets: 600 mg abacavir, 50 mg dolutegravir, and 300 mg lamivudine
For more information, visit viivpap.org.
TRIUMEQ PD
(abacavir, dolutegravir, and lamivudine)
Tablets for Oral Suspension: 60 mg abacavir, 5 mg dolutegravir, and 30 mg lamivudine
For additional information, please read the full Eligibility Requirements and Restrictions.
Tablets for Oral Suspension: 60 mg abacavir, 5 mg dolutegravir, and 30 mg lamivudine
For additional information, please read the full Eligibility Requirements and Restrictions.
Tablets for Oral Suspension: 60 mg abacavir, 5 mg dolutegravir, and 30 mg lamivudine
For more information, visit viivpap.org.
*All savings and assistance programs referenced on this site are subject to eligibility and program requirements and restrictions. These programs do not constitute health insurance. For more information, contact 1-844-588-3288.
†The ViiV Healthcare Patient Assistance Program is operated by the GSK Patient Access Programs Foundation, an independent, non-profit organization separate from ViiV Healthcare.
To report SUSPECTED ADVERSE REACTIONS, contact ViiV Healthcare at gsk.public.reportum.com or 1-877-844-8872, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
PMUS-HVXWCNT250001